HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $90

Benzinga · 6d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $145 to $90.